Canada markets closed
  • S&P/TSX

    18,480.98
    -521.72 (-2.75%)
     
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • DOW

    29,590.41
    -486.29 (-1.62%)
     
  • CAD/USD

    0.7359
    -0.0056 (-0.76%)
     
  • CRUDE OIL

    79.43
    -4.06 (-4.86%)
     
  • BTC-CAD

    25,753.46
    -370.41 (-1.42%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • GOLD FUTURES

    1,651.70
    -29.40 (-1.75%)
     
  • RUSSELL 2000

    1,679.59
    -42.72 (-2.48%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • NASDAQ

    10,867.93
    -198.87 (-1.80%)
     
  • VOLATILITY

    29.92
    +2.57 (+9.40%)
     
  • FTSE

    7,018.60
    -140.92 (-1.97%)
     
  • NIKKEI 225

    27,153.83
    -159.27 (-0.58%)
     
  • CAD/EUR

    0.7591
    +0.0055 (+0.73%)
     

Lonza's first-half core EBITDA gains 16.5%

·1 min read
FILE PHOTO: Logo of Swiss pharmaceutical group Lonza is seen in Basel

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies.

First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs.

For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

The company is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins as well as cell and gene therapies. Under the plan, Lonza earlier this month announced a 500 million franc investment in Switzerland to fill biotech drugs into vials.

The company, which is a key supplier of vaccine maker Moderna, is banking on long-term growth in the biopharmaceuticals sector well beyond the pandemic.

(Reporting by Ludwig Burger, Editing by Miranda Murray)